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of Intravenous and Oral Mycophenolate Mofetil
in Combination with Tacrolimus for GVHD Prophylaxis
in Pediatric Allogeneic Stem Cell Transplantation
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Monica Bhatia,1 Olga Militano,1 Zhezhen Jin,2 Michal Figurski,3 Leslie Shaw,3
Virginia Moore,1 Erin Morris,1 Bradford Tallamy,1 Carmella van deVen,1 Janet Ayello,1
LeeAnn Baxter-Lowe,4 Prakash Satwani,1 Diane George,1 M. Brigid Bradley,1 James Garvin,1
Mitchell S. Cairo1,5,6Acute graft-versus-host disease (aGVHD) still remains a major limiting factor following allogeneic stem cell
transplantation (AlloSCT) in pediatric recipients. Mycophenolate mofetil (MMF), an uncompetitive selective in-
hibitor of inosine monophosphate dehydrogenase, is a new immunosuppressant agent without major mucosal,
hepatic, or renal toxicity compared to other prophylactic aGVHD immunosuppressant drugs. Although there
has been an extensive pharmacokinetic (PK) experience with MMF administration following solid organ trans-
plantation in children, there is a paucity of PK data following its use in pediatric AlloSCTrecipients. We inves-
tigated the safety and PKof MMF as GVHD prophylaxis following intravenous (i.v.) and oral (p.o.) administration
(900 mg/m2 every 6 hours) in conjunction with tacrolimus, after myeloablative (MA) and nonmyeloablative
(NMA) conditioning and AlloSCT in 3 distinct age groups of pediatric AlloSCT recipients (0-6 years,
6-12 years, and 12-16 years). Mycophenolic acid (MPA) in plasma samples was measured either by high-perfor-
mance liquid chromatography (HPLC) or liquid chromatography/mass spectrometry (LC/MS/MS) as we have
previously described. Plasma samples were obtained at baseline and at 0.5, 1, 2, 3, 4, and 6 hours after i.v. dosing
on days11,17,114, and at 2 time points between day145 and1100 after p.o. administration post AlloSCT.
MPA PK analysis included AUC (0-6 hours), Cmax, Tmax, Css, Vss, C trough (C0), CL, and T½. Thirty-eight patients,
with a median age of 8 years (0.33-16 years), 20/18 M:F ratio, 21/17 malignant/nonmalignant disease, 17/21 MA:
NMA conditioning, 16 of 22 related/unrelated allografts. Median time to myeloid and platelet engraftment was
18 and 31 days, respectively. Mean donor chimerism on day 160 and 1100 was 83% and 90%, respectively.
Probability of developing aGVHD grade II-IVand extensive chronic GVHD (cGVHD) was 54%and 34%, respec-
tively. There was significant intra- and interpatient MMF PK variability. There was a significant increase in i.v.
MPA area under the curve (AUC)0-6hour and Cmax (P\ .0003) and a significant decrease in CLss (P\ .002)
and Vss (P\ .001) on day 114 versus day 17. Children\12 years of age had a significant increase in i.v.
MPA Tmax (P 5 .01), Vss (P 5 .028), and CLss (P\.001) compared to the older age group. There was a trend
in increased i.v. MPA CLss following MA versus NMA conditioning (P\.054); i.v. and p.o. MMF administration
(900 mg/m2 every 6 hours) in combination with tacrolimus was well tolerated in pediatric AlloSCTrecipients.
There was a significant increase in MPA exposure on day114 versus day17, suggesting improved enterohe-
patic recirculation at day114 post-AlloSCT. Children\12 years of age appear to have a significantly different
MPA PK profile compared to older children and adolescents and may require more frequent dosing.
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334 Biol Blood Marrow Transplant 16:333-343, 2010M. Bhatia et al.INTRODUCTION and the development of aGVHD and chronic GVHDAllogeneic stem cell transplantation (AlloSCT) re-
mains the only curative option for a number of pediat-
ric malignant and nonmalignant conditions [1]. Acute
graft-versus-host disease (aGVHD) is a potentially
fatal complication after AlloSCT, contributing to a
treatment-related mortality (TRM) of 15% to 30%
[2,3]. Current posttransplantation therapies for pro-
phylaxis and treatment of GVHD in pediatric recipi-
ents following AlloSCT are only partially effective [4].
Historically, cyclosporine A (CsA) and methotrex-
ate (MTX), with or without prednisone (PDN), have
been used for aGVHD prophylaxis after matched
related and unrelated AlloSCT, and have been shown
to be superior to either drug alone in preventing grade
II-IV aGVHD [5,6]. Despite the effectiveness of these
regimens, each of these agents are known to be associ-
ated with significant organ toxicity [7-9]. Tacrolimus
(FK506), another calcineurin inhibitor, is similar to
but 50 to 200 times more potent an immunosuppres-
sant than CsA [10,11]. In 3 randomized human trials,
FK506 in conjunction with standard low dose MTX
was associated with a significantly lower incidence of
aGVHD compared with CsA/MTX [12-14].
Mycophenolate mofetil (MMF) is an ester prodrug
of the immunosuppressant mycophenolic acid (MPA),
which is a potent, reversible, uncompetitive inhibitor
of inosine monophosphate dehydrogenase (IMPDH),
the rate-limiting enzyme for de novo purine synthesis
during cell division. T and B cell lymphocytes are more
dependent on this pathway than other cell types. The
rationale for the use of MMF in place of MTX was
in part to reduce the risk of mucosal, hematologic,
and hepatic side effects often associated with MTX
[15-21].
Although MMF is now more commonly utilized in
AlloSCT recipients, a scant amount of data is available
regarding the pharmacokinetics (PK) in pediatric Al-
loSCT recipients. Therefore, many centers have
extrapolated dosing based on that used in children un-
dergoing kidney transplantation (600 mg/m2 every 12
hours) or the common adult dose (15 mg/kg every 12
hours). We reported the preliminary results of the
safety of MMF and FK506 as GVHD prophylaxis in
pediatric AlloSCT recipients [20].
In the current study, we set out to investigate
whether MMF and/or its metabolite, MPA, might
have a different PK profile between different pediatric
age groups and the types of conditioning regimens
used (myeloablative [MA] versus nonmyeloablative
[NMA]) in pediatric AlloSCT. We report the age de-
pendent PK of intravenous (i.v.) and oral (p.o.)
MMF, respectively, in combination with tacrolimus
in the early (day 11 to day 114), and late (day 145
to day 1100) posttransplant period in pediatric Al-
loSCT recipients, stratified by conditioning regimens,(cGVHD) in this patient population.MATERIALS AND METHODS
Patients
From January 2004 to May 2008, we investigated
the safety profile and age dependent (\6 years, 6-12
years, and 12-16 years) PK of i.v. MMF, in combina-
tion with tacrolimus in the early posttransplant period
(day 11 to day 114) and p.o. MMF in the late post-
transplant period (day145 to day1100) in 38 pediat-
ric AlloSCT recipients, stratified by conditioning
regimen intensity (Table 1). We also evaluated the in-
cidence and severity of aGVHD following MMF/
FK506 prophylaxis in pediatric AlloSCT recipients,
stratified by allogeneic stem cell source and HLA dis-
parity. Pediatric patients #16 years of age with both
malignant and nonmalignant conditions, undergoing
AlloSCT from both related and unrelated donors us-
ing either MA or NMA conditioning regimens were
enrolled on a Columbia University Medical Center in-
stitutional review board (IRB)-approved protocol. An
investigational new drug (IND) exemption for this
study was granted by the Federal Food and Drug Ad-
ministration. All patients and/or parents signed an
IRB-approved informed consent and assent (when ap-
plicable) prior to study entry. Patients were excluded
from the study if they had a known history of hypersen-
sitivity to MMF, MPA, or polysorbate 80 (i.v. formu-
lation), or any ingredient of mycophenolate
formulation, had creatinine clearance \40 mL/min/
m2 (determined by Schwartz formula or nuclear glo-
merular filtration rate), or were pregnant or lactating
females. Patients receiving concomitant probenecid,
or aluminum and/or magnesium containing antacid
(for patients on p.o. MMF only) were ineligible for
PK analysis. Only patients scheduled to receive
GVHD prophylaxis with tacrolimus and MMF on
their AlloSCT protocols were eligible to enter the
study. Patients were removed from the study if they
reached day 1100 posttransplant, developed grade
IV toxicity (CTCAE version 3.0) to MMF, had equal
to or greater than grade II gastrointestinal GVHD
while on p.o. MMF, required to be switched from ta-
crolimus to another immunosuppressant agent for
GVHD prophylaxis or therapy, patient or parent with-
drawal from protocol, or death.GVHD Prophylaxis
FK506 was administered either i.v. at 0.03 mg/kg/
day by continuous infusion or p.o. at 0.12 mg/kg/day
in 2 or 3 divided doses starting on day21 or on the first
day of conditioning (protocol dependent) as we have
previously reported [20]. Doses were adjusted to
Table 1. Patient Characteristics
Number of patients 38
Median age (years, range) 8 (0.33-16)
Sex
Male 20 (53%)
Female 18 (47%)
Diagnosis/disease status (n 5 38)
Malignant (N 5 21)
ALL (1 CR1, 2 CR2, 1 CR3) 4
AML (6 CR1, 1 CR2, 1 CR3, 2 Rel, 1 PIF) 11
NHL (1 Ref) 1
HD (1 CR2) 1
CML-CP 1
Neuroblastoma (3 PR) 3
Nonmalignant (N 5 17)
SCD 4
Aplastic Anemia 8
WAS 1
Scleroderma 1
HLH 2
MDS 1
Prior transplant history
Autologous 4
Allogeneic transplant 1
Transplant cell source (allogeneic)/HLA disparity
Cord blood 21 (55%)
None (6/6) 5
5/6 8
4/6 8
Marrow 6 (16%)
None (6/6) 5
5/6 1
4/6 0
PBSC 11 (29%)
None (6/6) 7
5/6 3
4/6 0
8/10 1
Donor source
Related 18 (47%)
Unrelated 20 (53%)
Preparative regimen
Nonmyeloablative 21 (55%)
Myeloablative 17 (45%)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease;
CML-CP, chronic myelogenous leukemia in chronic phase; SCD, sickle
cell disease; WAS, Wiscott-Aldrich syndrome; HLH, hemophagocytic
lymphohistiocytosis; MDS, myelodysplastic syndrome; Rel, relapse;
Ref, refractory; PIF, partial induction failure; PBSC, peripheral blood
stem cell.
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ng/mL (Abbott IMX microparticle enzymatic immu-
noassay [MEIA]), and for tacrolimus-induced toxicity.
FK506 was changed to oral dosage when clinically ap-
propriate. MMF was administered daily starting on
day 11 at 900 mg/m2/dose i.v. (over 2 hours) every 6
hours (children\1 year of age or\10 kg received 30
mg/kg i.v. [over 2 hours] every 6 hours). Patients
were changed to p.o. MMF when clinically indicated
or on/around day 115 at the same dose and interval.
During the oral administration, an overnight
(8-hour) fasting period was required on days of PK
analysis. MMF doses were not modified based on mea-
sured MPA concentrations. In those with nonmalig-
nant diseases, MMF was tapered over 4 weeks
starting at day 1180. In those patients with malignantconditions receiving a related graft, MMF was stopped
at day 130 unless signs of equal to or greater than
grade II GVHD was present. In those receiving an
unrelated graft, MMF was stopped at day 160 unless
signs of equal to or greater than grade II GVHD was
present. Oral MMF was generously provided by Roche
Laboratories, Nutley, NJ. Commercially available i.v.
MMF was provided by the NewYork-Presbyterian
Hospital pharmacy.
GVHD was graded according to Seattle consensus
criteria [22]. The rule of ‘‘9’’ or a burn chart was used
to estimate the extent of skin rash. Patients were staged
and graded once a week for the occurrence of aGVHD.
Once a clinical diagnosis of aGVHD or cGVHD was
determined, histological confirmation was obtained if
possible.Sample Collection and Handling
Intravenous MMF PK sample collection
Total MPA calculations were done from the same
blood sample. Venous blood samples (2-3 mL) for PK
analysis (MPA total) during i.v. MMF administrations
were drawn though a central venous line (CVL) and
placed in EDTA tubes at time 0 (immediately before
dose), and at 0.5, 1, 2, 3, 4, and 6 hours after the admin-
istration of the morning IV MMF dose on days 11,
17, and 114.
Oral MMF PK sample collection
Venous blood samples (2-3 mL) for PK analysis
(MPA total) were drawn through a CVL and placed
in an EDTA tube at time 0 (immediately before
dose) and at 0.5, 1, 2, 3, 4, and 6 hours after the morn-
ing p.o. MMF dose on 2 different dates at least 1 week
apart during PO administration on days145 to1100.
All samples were placed on ice (4C) immediately,
then plasma was separated and frozen at 280C until
analysis.MPA Bioanalysis
MPA plasma samples were analyzed using 2
equivalent validated assays: high-performance liquid
chromatography (HPLC) [23] and liquid chromatog-
raphy/mass spectrometry (LC/MS/MS) [24]. In the
beginning of the study, HPLC-UV assay was used
(Agilent 1100 isocratic system with UV detection [Agi-
lent Technologies, Palo Alto, CA]; Column: Zorbax
Eclipse XDB-C18, 4.6  150 mm [Agilent Technolo-
gies]). Plasma samples were prepared as follows: 0.3
mL of plasma was treated with 1 mL of acetonitrile,
vortexed for 0.5 minutes, and centrifuged for 10 min-
utes at 3000 rpm, 10C, then 1 mL of supernatant
was removed and diluted 1:1 with water, vortexed, and
centrifuged again (same conditions). The lower limit
of quantification for this method was 0.1 mg/L of
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0.2, 2, and 15 mg/L of MPA, with precision of 0.95
to 5.2% and accuracy of 3.6 to 7.2%.
Approximately halfway through the study, the LC/
MS/MS assay was utilized (HPLC: Agilent 1100 sys-
tem composed of 2 pumps: isocratic and quaternary,
degasser, autosampler, and heated column compart-
ment. Column: Zorbax Eclipse XDB-C18, 4.6  150
mm [Agilent Technologies]; MS/MS: API 2000 tan-
dem Mass Spectrometer [MDS Sciex, Toronto,
Canada] with Valco 10-port switching valve and Ana-
lyst software, version 1.4). Plasma samples for LC/
MS/MS assay were prepared as follows: 1 mL of aceto-
nitrile was added to 0.1 mL of plasma, vortexed, and
centrifuged as discussed, diluted with water 1:2, then
vortexed and centrifuged again. The lower limit of
quantification for this method was 0.05 mg/L of
MPA. Three levels of quality controls were utilized:
0.5, 5.0, and 15 mg/L of MPA, with precision of 4.1%
to 4.5% and accuracy of 0.4% to 5.4%. The powder of
MPA generously donated by Roche Laboratories was
utilized for preparation of standard and controls.
MPA PK Analysis
For each patient, noncompartmental PK analysis
of total MPA concentrations was performed. Plasma
concentration-time data were analyzed using standard
spreadsheet software (OpenOffice 2.4, OpenOffi-
ce.org). The steady-state area under the curve (AUC)
0-6 hours was calculated using the linear trapezoidal
method [25]. Steady-state concentration (Css) was
computed by dividing AUC0-N by dosing interval (6
hours). Maximum concentration (Cmax) was deter-
mined by visual observation of the highest MPA
plasma concentration. Tmax was the time of Cmax, and
trough concentration (C0) was the concentration at
hour 6 post-MMF dose. MPA clearance was calculated
by dividing the total MMF dose by MPA AUC0-N.
Volume of distribution at steady state (Vss) was calcu-
lated by multiplying the MPA clearance by mean
retention time (MRT) of MPA. Half-life was calcu-
lated as a ratio of 0.693 and lambda. Lambda was the
slope of a line fitted to the last 3 points (after 2 hours
time point) on a semilogarithmic plot of MPA concen-
tration versus time.
Statistics
The continuous variables are summarized as mean
and standard deviation, the categoric variables are
summarized as percentage. The change in PK mea-
surements at 2 time points were assessed by the signed
rank test. The 2-sided t-test is used for comparing con-
tinuous variables in 2 groups and the analysis of vari-
ance (ANOVA) is used for comparing more than 2
groups. Probabilities of neutrophil recovery, platelet
recovery, aGVHD and cGVHD, and overall survival(OS) were estimated using the Kaplan-Meier method.
Curves were compared by the Log-rank test. Tests
with P\ .05 were considered significant. OS is defined
as the time between transplantation and death because
of any cause or between transplantation and May 31,
2008. Poor-risk patients were defined as patients
with malignant disease with refractory disease and/or
complete response (CR) 3 or beyond. The remaining
patients were classified as average risk.
The logistic regression was used for the analysis of
grade II-IV aGVHD. Variables for the risk of aGVHD
included age, sex, conditioning intensity, related ver-
sus unrelated donors, HLA 6/6 match versus others,
poor risk versus average risk, nonmalignant versus ma-
lignant, i.v. MMF aggregate day 17 and day 114 PK
(Cmax, Tmax, MPAtrough, AUC0-6, T½, Vss, Css, Clss).
Multivariate models were built based on the variables
that had a P-value of\.2 in the univariate analysis.RESULTS
Patient Demographics
Thirty-eight AlloSCT patients were studied
(Table 1). Twenty patients were male (53%) and 18
patients were female (47%) with a median age of 8
years (0.33-16 years). Twenty-one patients (55%)
were transplanted for malignant conditions and 17
patients (45%) were transplanted for nonmalignant
conditions. Donor sources were: umbilical cord blood
(UCB) (n 5 21, 55%), bone marrow (BM) (n 5 6,
16%), and peripheral blood stem cells (PBSC) (n 5
11, 29%) with 18 patients (47%) undergoing a related
SCT and 20 patients (53%) undergoing an unrelated
SCT. Four patients had undergone a prior autologous
SCT and 1 patient had a prior AlloSCT.Conditioning
The conditioning regimens were both MA (n5 17,
45%) and NMA (n 5 21, 55%). Of the MA regimens,
the majority contained busulfan (Bu) 12.8-16 mg/kg
(n 5 11, 65%); the remainder of the regimens were
either total body irradiation (TBI) based (n 5 4,
23%) or cyclophosphamide (Cy) 120-200 mg/kg
(n5 2, 12%). The NMA regimens all were fludarabine
(Flu; 150-180 mg/m2) based regimens (n5 21, 100%).Concurrent Medications
None of the patients enrolled in the study received
concomitant probenecid, aluminum, and/or magne-
sium containing antacids, CsA, or cholestyramine.
Even though acyclovir may potentially increase serum
concentrations of MPA, all patients received acyclovir
for HSV prophylaxis from day 0 until engraftment.
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Donor sources included 6 6/6 HLA-matched
sibling BM, 1 8/10 matched unrelated BM, 7 6/6
HLA-matched sibling PBSC, and 3 5/6 HLA matched
PBSC. The majority of patients underwent a UCB-
transplant (n 5 21, 55%) with 2 6/6 related UCB, 3
6/6 unrelated UCB, 8 5/6 UCB, and 8 4/6 UCB
(Table 1).
GVHD
Nineteen of 38 evaluable patients developed grade
II-IV aGVHD and 13 developed grade III-IV
aGVHD of the skin and intestine. The probability of
developing grade II-IV and III-IV aGVHD was
54.4% (CI95: 37.24-68.7) and 41.6% (CI95: 20.3-
61.7), respectively (Figure 1). A total of 9 patients de-
veloped extensive cGVHD; 5 patients who received
a related transplant and 4 patients who received unre-
lated transplants. The probability of developing
cGVHD in all patients was 33.7% (CI95: 15.0-52.3)
(Figure 1).
Grade III/IV Toxicity
Grade III toxicity directly, probably and possibly
because of MMF included nausea (8%), vomiting
(3%), diarrhea (5%), and gastritis (3%). There were
no grade III/IV hematologic toxicities definitely,
probably or possibly attributed to MMF. Also, no pa-
tients in our study developed Grade III/IV nephrotox-
icity thought to be attributed to tacrolimus.
Pharmacokinetics
Mean PK parameters following day 11, 7, and 14
i.v. MMF dosing and 2 p.o. MMF dosing between daysFigure 1. Probability of developing aGVHD or cGVHD. Probability of
developing aGVHD grade II-IV (), grade III-IV (), or cGVHD () deter-
mined by Kaplan Meier method in patients receiving AlloSCT.145 and1100 for all patients are depicted in Table 2.
Data was available in 27, 31, and 32 patients on days
11,17,114 following i.v. MMF dosing, respectively.
Limited data was available on patients following p.o.
MMF dosing between days 145 and 1100 because
of either death, disease progression, development of
severe aGVHD requiring continued i.v. MMF dosing,
inability to tolerate p.o. MMF, physician/patient pref-
erence, and/or institutional protocol requirements to
discontinue MMF at day 130. PK parameters were
highly variable with .10-fold interpatient variability
in total MPA AUC0-6 as well as total MPA trough con-
centration. There were no significant differences for
most MPA PK parameters on day 11 versus day 17
of dosing, with the exception of total MPA trough con-
centrations (0.33 versus 0.68 mg/L; P 5 .002). How-
ever, there were statistically significant differences in
most PK parameters on day17 versus day114 of dos-
ing: AUC0-6 and Cmax were increased significantly on
day 114 compared to day 17 (AUC: 33.71 versus
26.82 mgx h/L, P 5 .0003; Cmax: 16.54 versus 12.31
mg/L, P 5 .0003); whereas clearance and volume of
distribution were significantly decreased (CLss: 1.17
versus 1.40 L/h$kg, P 5 .002; Vss: 3.00 versus 3.35
L/kg, P 5 .001).
We next compared the i.v. (day 11, 17, and 114)
aggregate MMF PK between the 3 different age
groups (\6 years, 6-12 years, and $12 years). There
were no significant differences in the following MMF
PK parameters between age groups: Cmax, MPA
trough (C0), Css, AUC0-6, and T½ (Table 3A). Pairwise
comparison demonstrated no difference in Tmax be-
tween patients\6 years of age versus 6-12 years and
between 6-12 years versus .12 years age groups.
However, children \6 years of age had significant
higher Tmax compared to .12 years age group (P 5
.001) (Table 3A).
Similarly, there was no difference in CLss or Vss
between\6 years versus 6-12 years age group; patients
in the\6 years group had significant higher CLss and
Vss compared to patients .12 years (P 5 .02 for CLss;
P5 .014 for Vss) and the 6-12 years age group had sig-
nificant higher CLss compared to .12 years group
(P 5 .001). When #12 years age group was compared
to the .12 years group, the results revealed that Tmax,
Vss and CLss in the #12 years group were significantly
higher than those in the .12 years group (P 5 .01 for
Tmax; P 5 .028 for Vss and P 5 .001 for CLss) (Table
3A). There was no significant difference in MMF PK
between the 3 different age groups following p.o.
MMF administration (Table 3B) (Cmax: P 5 .11, Tmax:
P 5 .25, MPA: P 5 .64, AUC0-6: P 5 .06, T½: P 5
.45, CLA: P5 .42, Vss: P5 .34 and Css: P5 .28).
We next compared the MMF PK following i.v.
MMF (days 11, 17, and 114) in pediatric AlloSCT
recipients following MA versus NMA conditioning
(Table 3C). The intensity of conditioning had no
Table 2. Mean PK Parameters (All Patients)
i.v. MMF Administration MMF p.o. First
t Sample MMF p.o. Second Sample
Mean PK Values Day +1 (SD) [N 5 27] Day +7 (SD) [N 5 31] Day +14 (SD) [N 5 32] Day +45-100 (SD) [N 5 15] Day +45-100 (SD) [N 5 9]
Cmax (mg/L) 15.4 (19.71) 12.31 (7.99)† 16.54 (13.24)† 13.15 (12.04) 13.20 (8.86)
Tmax (h) 1.87 (0.47) 1.92 (0.55) 1.75 (0.44) 1.7 (0.98) 1.33 (0.83)
C0 (mg/L) 0.33 (0.29)* 0.68 (0.56)* 0.72 (0.62) 1.45 (1.46) 1.43 (1.37)
Css (mg/L) 5.45 (6.34) 4.73 (2.22) 6.46 (4.07) 5.38 (3.55) 6.54 (3.55)
AUC0-6 (mg h/L) 32.06 (38.09) 26.82 (12.35)† 33.71 (16.86)† 26.50 (19.03) 26.70 (15.81)
CLss (L/h$kg) 1.46 (1.04) 1.40 (0.63) * 1.17 (0.63) * 2.21 (1.43) 1.46 (1.01)
Vss (L/kg) 3.04 (1.91) 3.35 (1.58) ‡ 3.00 (2.05)‡ 9.77 (8.93) 18.33 (35.74)
T1/2 (h) 1.02 (0.69) 1.35 (1.01) 2.49 (6.77) 3.17 (2.63) 10.19 (18.06)
SD indicates standard deviation; MMF, mycophenolate mofetil; Cmax, maximum concentration; Tmax, time of maximum concentration; C0, trough con-
centration; Css, steady-state concentration; AUC0-6, steady-state area under the curve 0-6 hours; CLss, steady-state clearance; Vss, volume of distribu-
tion; T½ half-life.
*P 5 .002.
†P 5 .0003.
‡P 5 .001.
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tioning (Table 3C), although there was a very strong
trend with increase in CLss (1.55 versus 1.15) in MA
versus NMA conditioning (P\ .054).
Multivariate Analysis
We determined the effect of age, sex, conditioning
intensity, related versus unrelated donor, HLA (6/6
versus other), poor versus average risk, malignant ver-
sus nonmalignant, and i.v. MMF PK in aggregate and
day 17 and day 114 (Cmax, Tmax, T½, MPAtrough,
AUC0-6, Css, Vss, and CLss) on the probability of devel-
oping grade II-IV aGVHD. Although MA condition-
ing, HLA\6/6, malignant disease and day17 Cmax all
were\0.2 in the univariate analysis (Table 4). None of
these variables were independently associated with
grade II-IV aGVHD in the multivariate analysis.
Survival
The OS for all 38 patients was 61.8% (95% confi-
dence interval [CI]: 48.3-78.4) (Figure 2).DISCUSSION
In our previous pilot study, we demonstrated in 34
children and adolescents with malignant and nonma-
lignant disease following 37 AlloSCT, that the pro-
phylactic use of MMF at 15 mg/kg i.v. or p.o. everyTable 3A. Mean PK Parameters by Age (Combined i.v. Aggregate
Age group n Cmax mg/L (SD) Tmax h (SD) C0 mg/L (SD) Css mg/L (S
<6 yrs 14 13.85 (5.94) 1.89 (0.36) 0.65 (0.56) 5.20 (1.63
6-12 years 10 15.93 (10.65) 2.03 (0.11) 0.49 (0.34) 5.90 (3.67
$12-16 years 12 14.12 (7.07) 1.63 (0.44)* 0.67 (0.42) 5.72 (3.00
PK indicates pharmacokinetic; i.v., intravenous; Cmax, maximum concentration
steady-state concentration; AUC0-6, steady-state area under the curve 0-6 ho
SD, standard deviation.
*ANOVA P-value 5 .01 (#12 years versus >12 years).
†ANOVA P-value 5 .001(#12 years versus >12 years).
‡ANOVA P-value 5 .028 (#12 years versus >12 years).12 hours failed to achieve a solid organ transplant tar-
get MPA trough level of 1-3.5 mg/L [20]. Eight of
those 34 patients received an escalated dose of 900
mg/m2 i.v. every 6 hours of MMF and obtained an
MPA trough level of between 1 and 3.5 mg/L [20].
There was no evidence of increased systemic toxicity
following this increase in the dose of MMF [20]. In
the current study, this increased dose of MMF (900
mg/m2 every 6 hours) was given prophylactically in pe-
diatric AlloSCT recipients. Unfortunately, our earlier
observations did not hold up in the present analysis in
terms of ability to achieve target trough concentrations
at the earlier dose as well as the utility of measuring
trough concentrations. Recent data in both adults
and pediatric AlloSCT recipients suggests the lack of
utility of trough concentrations predicting rejection/
engraftment and/or risk of GVHD [26,27]. The major
known toxicities of MMF, particularly after solid or-
gan transplantation, has included toxicities to the gas-
trointestinal tract [28]; in particular, nausea and
vomiting, and hematopoietic toxicity, especially neu-
tropenia. In the present study, there was a 3% inci-
dence of grade III vomiting and gastritis, a 5%
incidence of grade III diarrhea, and an 8% incidence
of grade III nausea. This incidence of low-grade gas-
trointestinal toxicity appears to be similar to previous
reports of the use of MMF in adult AlloSCT recipients
[16,18,27,29-31] Similarly, there did not appear to be
any evidence of any delay in hematopoietic)
D) AUC0-6 mg h/L (SD) CLss L/h$kg (SD) Vss L/kg (SD) T1/2 h (SD)
) 29.46 (9.80) 1.65 (0.59) 3.87 (1.39) 1.20 (0.66)
) 34.28 (21.19) 1.45 (0.67) 3.22 (1.56) 1.22 (0.51)
) 28.60 (8.92) 0.88 (0.36)† 2.44 (1.36)‡ 2.86 (5.48)
; Tmax, time of maximum concentration; C0, trough concentration; Css,
urs; CLss, steady-state clearance; Vss, volume of distribution; T½, half-life;
Table 3B. Mean PK Parameters by Age (Combined p.o. Aggregate)
Age Group n Cmax mg/L (SD) Tmax h (SD) C0 mg/L (SD) Css mg/L (SD) AUC0-6 mg h/L (SD) CLss L/h$kg (SD) Vss L/kg (SD) T1/2 h (SD)
<6 years 9 14.70 (10.85) 1.36 (0.82) 1.83 (1.48) 5.66 (3.64) 30.18 (19.23) 2.07 (1.05) 8.81 (7.26) 3.32 (2.70)
6-12 years 5 7.03 (5.23) 2.20 (1.15) 1.12 (1.15) 4.49 (2.35) 16.57 (8.01) 2.27 (1.41) 19.09 (25.58) 8.40 (12.46)
$12-16 years 2 11.85 (11.17) 1.63 (0.53) 1.24 (1.30) 6.07 (0.77) 25.51 (10.26) 0.68 (0) 1.46 (0) 3.36 (3.53)
PK indicates pharmacokinetic; p.o., oral; Cmax, maximum concentration; Tmax, time of maximum concentration; C0, trough concentration; Css, steady-
state concentration; AUC0-6, steady-state area under the curve 0-6 hours; CLss, steady-state clearance; Vss, volume of distribution; T½, half-life; SD, stan-
dard deviation.
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These safety results compare favorably to adult Al-
loSCT recipients who tend to receive 25% to 50%
of MMF compared to the dose utilized in this prophy-
lactic pediatric AlloSCT trial [15,16,18,27,29-31].
The bioavailability of MMF after p.o. administra-
tion in healthy individuals has been reported to be
approximately 94% [32]. MMF is rapidly hydrolyzed
by esterases to form the active compound MPA [32].
There has been extensive experience in both adults
and children receiving solid organ transplants demon-
strating that targeting either the total predose MPA
trough concentration between 1 and 3.5 mg/L (with
concomitant CsA) or 1.9 to 4 mg/L (with concomitant
tacrolimus) and/or MPA Css 2.5 to 5 mg/L has been
successfully associated with a decrease in allograft
rejection and a reduction in MMF-associated toxicities
[33-35].Last, Kagaya et al. [36] demonstrated no PK
interactions between MPA and tacrolimus following
adult renal solid organ transplantation, suggesting
that MMF and tacrolimus can be safely combined.
Therapeutic drug monitoring (TDM) following
MMF administration in patients after either solid
organ or AlloSCT has been controversial, and is fur-
ther complicated by the specific manner in which
MMF is metabolized [37]. Specifically, MPA, the ac-
tive metabolite of MMF, is conjugated to the pharma-
cologically inactive phenolic glucuronide (MPAG),
which is excreted primarily by the kidney. The PK of
MMF, however, is further complicated by enterohe-
patic circulation of MPAG, which is excreted into
the bile and which is subsequently hydrolyzed in the
intestine and reabsorbed as MPA, giving rise to sec-
ondary peak of MPA, 6 to 12 hours after MMF admin-
istration [38]. Furthermore, MPA binds extensively to
plasma albumin and has a free MPA fraction of\3%
[38]. Additional confounding factors include signifi-
cant intra- and interpatient variability followingTable 3C. Mean PK Parameters (Combined i.v. Aggregate) Stratifi
Conditioning n Cmax mg/L (SD) Tmax h (SD) C0 mg/L (SD) Css mg/L (S
MA 17 15.12 (7.40) 1.83 (0.46) 0.53 (0.37) 5.20 (1.46
NMA 19 13.98 (8.07) 1.85 (0.29) 0.69 (0.51) 5.90 (3.49
PK indicates pharmacokinetic; MA, myeloablative; NMA, nonmyeloablative; Cm
trough concentration; Css, steady-state concentration; AUC0-6, steady-state are
distribution; T½, half-life; SD, standard deviation.MMF administration and that coadministration of
CsA appears to decrease exposure of MPA as well
[39-41]. Therefore, a number of variables affect
MPA PK, including intra- and interpatient variability,
enterohepatic recirculation, renal function, albumin
level, and concomitant immunosuppressive therapy.
MMF PK has been extensively studied in adult Al-
loSCT recipients following both MA and NMA condi-
tioning [27,30,31]. The dosing of MMF in adult
AlloSCT recipients has been variable, and has ranged
between 12.5 mg/kg every 12 hours to 15 mg/kg every
6 hours [27,30,31]. The total MPA AUC0-6 has ranged
between 16.4 and 29 mg$h/L [27,30,31]. The MPA
Cmax has ranged between 1.0 and 29 mg/L (Table 5)
[27,30,31]. The MPA trough has ranged between
0.01 to 22 mg/L (Table 5) [27,30,31]. Last, the MPA
T½ has ranged between 0.8 and 7.9 hours (Table 5)
[27,30,31]. The influence of MA versus NMA condi-
tioning on MMF PK in adult AlloSCT recipients has
not demonstrated any significant differences to date
(Table 5) [27,30,31]. In the adult AlloSCT MMF PK
studies, few studies have been able to demonstrate
achieving an MPA Css between 2.5 and 5 mg/L, or an
MPA trough between 1 and 3.5 mg/L (concomitant
CsA) or 1.9 and 4 mg/L (concomitant tacrolimus) as
was suggested to be the target ranges following solid
organ transplantation [27,30,31,33-35]. Nash et al.
[27] demonstrated that total MPA Css . 2.5 mg/L is
achievable with either every 8 hours or every 6 hours
MMF dosing, however, not with q12 h dosing in adult
AlloSCT recipients [27].
In the most comparable adult AlloSCT study to our
current study, Nash et al. [27], investigated the PK of
MMF (450 mg/m2 [15 mg/kg] administered every 6
hours, every 8 hours, or every 12 hours) in combination
with CsA following MA conditioning in adult AlloSCT
recipients [27]. Nash et al. [27] demonstrated on day 14
a median MPA AUC0-6 of 29 mg$h/L, MPA clearanceed by MA versus NMA Conditioning
D) AUC0-6 mg h/L (SD) CLss L/h$kg (SD) Vss L/kg (SD) T1/2 h (SD)
) 29.77 (8.92) 1.55 (0.68) 3.53 (1.75) 1.20 (0.61)
) 31.18 (16.79) 1.15 (0.54) 2.93 (1.25) 2.26 (4.37)
ax, maximum concentration; Tmax, time of maximum concentration; C0,
a under the curve 0-6 hours; CLss, steady-state clearance; Vss, volume of
Table 4. Risk of Developing Grade II-IV Acute Graft-versus-
Host Disease by Univariate Analysis
Variable Odds Ratio 95%CI P-Value
Conditioning intensity
Nonmyeloablative 1.0
Myeloablative 2.44 (0.7-9.13) .18
HLA match
<6/6 1.0
6/6 0.27 (0.07-1.05) .059
Disease
Nonmalignant 1.0
Malignant 3.7 (0.95-14.09) .059
Day +7 i.v. MMF PK Cmax 1.1 (0.96-1.27) .1722
MMF indicates mycophenolate mofetil; CI, confidence interval.
340 Biol Blood Marrow Transplant 16:333-343, 2010M. Bhatia et al.of 0.54 L/h$kg, MPA Cmax of 11.4 mg/L, MPA trough
of 0.61 mg/L, MPA Css of 4.84 mg/L and MPA T½ of
0.87 hours [27]. In this study there was a suggestion
of increased toxicity without improved efficacy in the
every 6 hours dosing level. In contrast, we utilized twice
the dose of MMF in pediatric AlloSCT recipients fol-
lowing both MA versus NMA conditioning and dem-
onstrated a mean AUC0-6 of 29.77 versus 31.18 mg h/
L, mean MPA clearance of 1.55 versus 1.15 L/h$kg,
mean MPA Cmax of 15.12 versus 13.98 mg/L, a mean
MPA trough of 0.53 versus 0.69 mg/L, mean Css of
5.2 versus 5.9 mg/L, and a mean T½ of 1.2 versus 2.26
hours, respectively (Table 4).
There has been 1 other MMF PK study performed
in pediatric AlloSCT recipients following MMF dos-
ing of 15 mg/kg i.v. every 8 hours by Jacobson et al
[26]. Jacobson et al. [26] reported MMF PK results
in 19 pediatric AlloSCT recipients #10 years of age
following MA conditioning (n5 15) and in NMA con-
ditioning (n 5 4). Steady-state PK sampling was per-Figure 2. Probability of OS. Probability of OS determined by Kaplan
Meier method in all patients following AlloSCT.formed at 2 different time points (between day 13
and 17 [week 1], and repeated between day 110 and
114 [week 2]). In comparison to our study, Jacobson
et al. [26] reported a median MPA Css of 1.6 mg/L, to-
tal MPA trough concentration of 0.27 mg/L, and me-
dian MPA Cmax of 5.0 mg/L (median of combined
values for week 1 and week 2 post-AlloSCT) [26]. Sim-
ilarly to our study, there was considerable interpatient
variability in AUC and MPA trough values. The lower
MPA Css, Cmax, and MPA trough values reported in
Jacobson et al. [26] study are explained by significantly
lower doses of MMF (15 mg/kg dose is approximately
equivalent to 450 mg/m2) and longer frequency inter-
val (8 hours versus 6 hours in our study).
Furthermore, our study failed to demonstrate any
relationship between MMF PK following MA condi-
tioning, versus NMA conditioning, which is consistent
with reports in adult AlloSCT recipients [27,30,31].
One of the reasons we did not see a difference in
MMF PK based on a regimen intensity is because the
majority of our reduced-intensity regimens were
rather more of moderate intensity (based on 4 days
of Bu plus Flu or high-dose Cy plus Flu, rather then
traditional reduced-intensity of 200 cGy TBI/Flu
used in the adult studies), which are capable of produc-
ing a significant amount of Grade I-II gastrointestinal
toxicity, thus, still potentially affecting enterohepatic
recycling. This is a potential limitation of our study.
Our study did demonstrate a significant increase with
time in MMF PK from day 7 to day 14. We demon-
strated a significant increase in MPA AUC and MPA
Cmax on day 14 versus day 7, which resulted from a sig-
nificant decrease inCLss and Vss on day 7 versus day 14.
The detailed mechanism(s) responsible for this time-
dependent exposure increase in this patient population
is not known. This could be the result of the influence
of several factors including an increase in mucosal
healing following conditioning that leads to improved
drug absorption and to increased enterohepatic recir-
culation on day 14 versus day 7. Another factor that
could contribute to the time-dependent clearance
decrease of MPA is the presence of a hypermeta-
bolic/hypercatabolic state in many of these patients,
which causes increased drug clearance initially but
which normalizes with time [42,43]. Furthermore,
there was a significant increase in CLss, Vss, and Tmax
in children #12 years versus the older age group.
This preliminary age effect should be confirmed in
a larger pediatric cohort.
Another potential limitation of the current study is
that we did not monitor prospectively for other drug
interactions with MMF besides those mentioned in
the Methods section of this article. There may have
been patients receiving concurrent metronidazole,
fluoroquinolones, proton pump inhibitors, or ganci-
clovir, all of which can either decrease or increase
MPA concentrations.
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aGVHD and cGVHD was 54% (95% CI: 37%-
69%) and 34% (95% CI: 15%-52%) in this study,
respectively. Although we utilized a higher dose of
MMF prophylaxis (900 mg/m2 every 6 hours), we
were not able to demonstrate a decrease in the inci-
dence of grade II-IV aGVHD compared to other pedi-
atric AlloSCT trials [4]. Furthermore, although the
numbers were small, i.v. MMF PK in aggregate and
on days 17 and 114 has no independent effects on
the rate of aGVHD in our multivariate analysis.
In summary, we have demonstrated the safety and
PK of both i.v. and p.o. MMF (900 mg/m2 every 6
hours) following MA and NMA conditioning in pedi-
atric AlloSCT recipients. There was a significant in-
crease in MPA AUC0-6hr and Cmax associated with
a significant decrease in MPA CLss and Vss following
i.v. MMF on day 114 versus day 17. Furthermore,
children\12 years old appear to have a significant in-
crease inCLss,Vss, andTmax compared to 12 to 16 years
age groups following i.v. MMF administration. There
did not appear to be age differences following p.o.
MMF administrations; however, the numbers were
too small to draw any firm conclusions. There were
no significant differences in i.v. MMF PK following
MA versus NMA conditioning. In general, this in-
creased dose of MMF was well tolerated in children.
In patients exhibiting signs and symptoms of MMF
toxicity (gut or BM) we would recommend obtaining
MMF trough concentrations and adjusting doses
when elevated MPA levels are present. Monitoring of
MMF trough concentrations should be considered in
patients at high risk of gut GVHD or when gut absorp-
tion is impaired, with consideration of adjustment of
dose or frequency of MMF administration when
MPA levels are undetectable. Ideally, steady-state
levels (aiming for concentrations $2.5 mg/mL) [30]
should be monitored over trough concentrations as
they are more accurate, but the authors recognize
that this is not always feasible under nonresearch con-
ditions. Future studies will need to be performed to de-
termine the precise MPA C0, AUC and/or Css required
to best prevent aGVHD following AlloSCT in pediat-
ric recipients. Last, these results suggest because of
a significant interpatient variation, individualized
MMF PK measurements may be required in selected
pediatric AlloSCT recipients if clinically indicated
post transplantation, because the optimal MMF dose
and frequency after AlloSCT remains to be elucidated.ACKNOWLEDGMENTS
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